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Current treatment options for castration-resistant pros-
tate cancer (CRPC) are limited. In this study, a high-
throughput screen of 4910 drugs and drug-like mole-
cules was performed to identify antiproliferative com-
pounds in androgen ablated prostate cancer cells. The 
effect of compounds on cell viability was compared in 
androgen ablated LNCaP prostate cancer cells and in 
LNCaP cells grown in presence of androgens as well 
as in two non-malignant prostate epithelial cells 
(RWPE-1 and EP156T). Validation experiments of 
cancer specific anti-proliferative compounds indicated 
pinosylvin methyl ether (PSME) and tanshinone IIA as 
potent inhibitors of androgen ablated LNCaP cell pro-
liferation. PSME is a stilbene compound with no previ-
ously described anti-neoplastic activity whereas tanshi-
none IIA is currently used in cardiovascular disorders 
and proposed as a cancer drug. To gain insights into 
growth inhibitory mechanisms in CRPC, genome-wide 
gene expression analysis was performed in PSME- and 
tanshinone IIA-exposed cells. Both compounds altered 
the expression of genes involved in cell cycle and ster-
oid and cholesterol biosynthesis in androgen ablated 
LNCaP cells. Decrease in androgen signalling was 
confirmed by reduced expression of androgen receptor 
and prostate specific antigen in PSME- or tanshinone 
IIA-exposed cells. Taken together, this systematic 
screen identified a novel anti-proliferative agent, 
PSME, for CRPC. Moreover, our screen confirmed 
tanshinone IIA as well as several other compounds as 
potential prostate cancer growth inhibitors also in an-
drogen ablated prostate cancer cells. These results pro-
vide valuable starting points for preclinical and clinical 
studies for CRPC treatment. 
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High-throughput cell-based compound screen identifies pinosylvin methyl 
ether and tanshinone IIA as inhibitors of castration-resistant prostate 
cancer 
androgens are produced in cancer cells (Locke et al. 
2008, Taichman et al. 2007). Thus, AR and its co-
regulators are potent drug targets for CRPC treatment. 
Recently, novel promising anti-androgens and chemo-
therapeutic agents such as Enzalutamide, have been 
developed to target CRPC (Aragon-Ching 2012, Ber-
ruti et al. 2012, Dhingra et al. 2013, Schrader et al. 
2013). Although these anti-androgens and chemothera-
peutics have shown significant increase in patient sur-
vival by lengthening survival time by several months, 
there is a need for better treatment options to further 
improve the outcome of patients suffering from CRPC. 
 We have previously applied high-throughput 
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Introduction 
 
Androgen deprivation, surgery and radiation therapy 
are the main treatment options for prostate cancer pa-
tients. However, hormonal therapy is not curative and 
leads to the development of castration-resistant pros-
tate cancer (CRPC). The median survival time for 
CRPC is around 2 years (Tannock et al. 2004). Several 
mechanisms underlying CRPC development have been 
described: androgen receptor (AR) overexpression sen-
sitizing cancer cells to low levels of androgens, AR 
mutations enabling non-androgenic ligands to activate 
the receptor and intra-tumoral steroidogenesis in which 
screening to systematically explore most currently 
marketed drugs and drug-like molecules for their effi-
cacy against a panel of prostate cells (Iljin et al. 2009). 
Here, we performed a cell-based viability screen with a 
library of 4910 drug-like small molecule compounds in 
LNCaP prostate cancer cells grown either in presence 
or in absence of androgens (Culig et al. 1999). The 
androgen-independent derivative of the androgen-
dependent LNCaP prostate cancer cell line used in this 
study had been previously generated by long-term an-
drogen deprivation (Culig et al. 1999). The screening 
results from LNCaP cells were compared to the previ-
ous cell viability results in non-malignant prostate 
epithelial cells RWPE‑1 and EP156T to identify can-
cer-selective compounds (Iljin et al. 2009). Out of the 
growth inhibitory compounds identified in LNCaP 
cells, pinosylvin methyl ether (PSME) and tanshinone 
IIA were chosen for further analysis due to their cancer 
selective anti-proliferative effect in androgen ablated 
prostate cancer cells. 
 
Materials and Methods 
 
Cells  
Parental (LNCaP-par) and androgen ablated LNCaP 
(LNCaP-abl) prostate carcinoma cell lines were ob-
tained from Zoran Culig (Culig et al. 1999) and grown 
in RPMI‑1640 medium containing 10% FBS (LNCaP-
par) or 10% charcoal:dextran stripped FBS (LNCaP-
abl) supplemented with 1% glutamate and 1% penicil-
lin-streptomycin.  
 
Compounds 
Tanshinone IIA was purchased from Apin Chemicals 
Ltd. (Abingdon, UK) and pinosylvin methyl ether was 
purchased from Gentaur (London, UK). Both com-
pounds were dissolved in DMSO. 
   
High‑throughput screening (HTS) 
A high-throughput compound screening was per-
formed twice in LNCaP-par and LNCaP-abl cells us-
ing cell viability as the endpoint. The results were 
compared to the ones from our previous screen per-
formed in non-malignant RWPE-1 and EP156T cells 
with the same compound libraries and concentrations 
used in this study (Iljin et al. 2009). Briefly, 4910 
compounds, including experimental compounds, most 
of the existing Food and Drug Administration–
approved drugs, kinase and phosphatase inhibitors as 
well as natural products, were screened with at least 
two different concentrations. The cell viability was 
determined after a 3‑day incubation (1500 cells per 
well in 384-well format) with the compounds using a 
CellTiter-Glo (CTG) fluorescent cell viability assay 
(Promega, Inc.). The compounds that qualified as hits 
inhibited cell viability (loess‑score) by at least three 
standard deviations from the median of the controls. 
 
Cell viability and apoptosis assays 
Cell viability and apoptosis assays were performed on 
384-well plates (Falcon) by plating 2,000 cells per well 
in 35 μl of their respective growth media and left to 
attach overnight. Next, compound dilutions were 
added to the cells, plates were incubated for 48 hours 
and cell viability was determined using CellTiter-Blue 
(CTB) or CTG cell viability assay (Promega, Inc.) ac-
cording to the manufacturer’s instructions. Induction 
of caspase-3 and 7 activities was detected with ho-
mogenous Apo-ONE assay (Promega, Madison, WI). 
The fluorometric signal from CTB (excitation FITC 
485 nm, emission FITC 535 nm) or luminescence sig-
nals (700 nm) from CTG and apoptosis assays were 
quantified using Envision Multilabel Plate Reader 
(Perkin-Elmer, Massachusetts, MA). 
 
Gene expression analysis using bead-arrays 
Ablated and parental LNCaP cells were grown into 
approximately 70% confluence and treated with PSME 
or tanshinone IIA for 24 h before harvesting. Total 
RNA was extracted using RNeasy (Qiagen) according 
to the manufacturer’s protocol and the integrity of the 
RNA was monitored prior to hybridization using a 
Bioanalyzer 2100 (Agilent, Santa Clara, CA) accord-
ing to manufacturer’s instructions. 500 ng of purified 
RNA was amplified with the TotalPrep Kit (Ambion, 
Austin, TX) and the biotin labelled cRNA was hybrid-
ized to Sentrix HumanRef-8 vs.3 Expression Bead-
Chips (Illumina, San Diego, CA) while the arrays were 
scanned with the BeadArray Reader (Illumina). 
 
Statistical analysis of gene expression data 
The raw gene expression data were quantile-
normalized and analyzed with the R / Bioconductor 
software as previously described (Gentleman et al. 
2004, He et al. 2014). Differentially expressed genes 
from microarray hybridizations were identified using 
the significance analysis of microarrays program 
(SAM), with a false discovery rate set to zero and a 
minimum fold change of > 1.4. Hierarchical clustering 
and multidimensional scaling with principal coordi-
nates analysis was performed to visualize the distribu-
tion of prostate cell lines based on their compound re-
sponses. The functional gene ontology and pathway 
annotations were analyzed for differentially expressed 
genes (R>0.5 and p<0.001) using Ingenuity Pathway 
Analysis (IPA) Software (Ingenuity Systems Inc., Red-
wood City, CA, USA).  
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Quantitative reverse transcriptase PCR 
Reverse transcription using 500 ng of total RNA was 
performed with Applied Biosystem´s cDNA synthesis 
kit. TaqMan gene expression probes and primers from 
the Universal Probe Library (Roche Diagnostics, 
Espoo, Finland) were used to study androgen receptor 
(AR), prostate specific antigen (PSA) and β-actin 
mRNA expression. Primer sequences are listed in Sup-
plementary Table 1. Real-time quantitative PCR was 
performed using ABI Prism 7900 (Applied Biosys-
tems, Foster City, CA). Quantitation was carried out 
using the ΔΔCT method with the RQ manager 1.2 soft-
ware (Applied Biosystems). β-actin was used as an 
endogenous control. Average expression of the control 
samples was considered for the calculation of the fold 
changes. Two to four replicate samples were studied 
for quantitation of mRNA expression.  
 
Western blot analysis 
LNCaP-par and LNCaP-abl cells were plated at 70 % 
confluency and left to attach over night before treat-
ments with indicated compounds. 10 µg of total pro-
tein was denatured at 95 °C for 5 min in Laemmli 
buffer, separated on 10 % precast SDS-polyacrylamide 
gel (Lonza, Basel Switzerland) and transferred to Pro-
tran nitrocellulose transfer membrane (Schleicher & 
Schuell, Niedersachsen, Germany). Western blot 
analysis was performed using specific antibodies 
against AR (1:1000 dilution, mouse monoclonal, Lab-
vision, Fremont, CA), prostate specific antigen (PSA, 
1:1000, rabbit polyclonal, DakoCytomation, Den-
mark), and β-actin (1:4000 dilution, mouse-
monoclonal, Becton Dickinson, Franklin Lakes, NJ). 
Signal was detected with 1:4000 dilutions of appropri-
ate HRP-conjugated secondary antibodies (all from 
Invitrogen Molecular Probes, Carlsbad, CA) followed 
by visualization with the enhanced chemiluminescence 
reagent (Amersham Biosciences, Little Chalfont, UK).  
 
Results 
 
Identification of selective antineoplastic compounds 
for castrate-resistant prostate cancer 
To identify novel selective antineoplastic compounds 
and to explore targetable molecular pathways for cas-
trate-resistant prostate cancer, we carried out a cell-
based high-throughput screen (HTS) in LNCaP cells 
grown in absence (LNCaP-abl) and presence (LNCaP-
par) of androgens. Altogether, the effect of 4910 mar-
keted drugs and small molecule compounds on cell 
viability was measured after 3-day incubation with 
compounds. Cell viability results were compared to the 
results from previous screens performed in RWPE‑1 
and EP156T non-malignant prostate epithelial cells 
(Iljin et al., 2009). The anti-proliferative hit com-
pounds inhibited cell viability (loess‑score) by at least 
three standard deviations from the median of the con-
trols. To visualize the distribution of prostate cell lines 
based on their compound responses, hierarchical clus-
tering and multidimensional scaling with principal 
component analysis was performed. The results indi-
cated that normal epithelium-derived cell lines formed 
one group and the prostate cancer cell lines formed 
another group where separate clusters could be found 
for LNCaP –abl and LNCaP-par cells (Figure 1A and 
B).  
 In total, 44 cancer cell selective anti-
proliferative compounds qualified as hits in both inde-
pendent LNCaP-abl screens (Supplementary Table 2). 
Most of these compounds reduced cell viability also in 
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Figure 1. The distribution of prostate cells based on their 
compound responses demonstrated by using (A) hierarchical 
clustering and (B) multidimensional scaling with principal 
component analysis. Normal epithelium-derived cell lines 
formed one group and LNCaP prostate cancer cells grown in 
presence (LNCaP-par) and absence of androgens (LNCaP-
abl) formed separate clusters.  
LNCaP-par cells at least in one of the two screens. 
These compounds included drugs such as methotrexate 
and methotrexate hydrate, currently used in prostate 
cancer chemotherapy (Straus et al. 1982) as well as 
Jun N-terminal kinase inhibitor (SP600125) and PI3-
kinase inhibitors (LY294002 and Wortmannin) previ-
ously shown to induce apoptosis in prostate cancer 
cells (Bennett et al. 2001, Lin et al. 1999, Tyagi et al. 
2003). In addition, hypericin, an Hsp90 and HIF-1α 
degradator, known to reduce prostate cancer cell 
growth in vitro and in vivo (Barliya et al. 2011, Co-
lasanti et al. 2000, Xie et al. 2001), was identified 
among LNCaP-abl anti-proliferative hits. Moreover, 
aldehyde dehydrogenase (ALDH) inhibitor disulfiram, 
antibiotic monensin, fungicide thiram and HDAC in-
hibitor tricostatin A (TSA), that we previously identi-
fied as cancer-selective compounds using a panel of 
cultured prostate cells, also inhibited the viability of 
LNCaP-abl prostate cancer cells (Iljin et al. 2009). 
Furthermore, HDAC inhibitor SAHA, previously 
shown to inhibit ERG-positive prostate cancer cell 
growth (Bjorkman et al. 2008), reduced LNCaP-abl 
cell proliferation as well. Interestingly, one of the anti-
proliferative agents identified in both LNCaP-abl and 
LNCaP-par screens was microtubule polymerization 
interfering agent Nocodazole. It has been shown to 
block nuclear translocation of AR and ablate dihydro-
testosterone induced PSA expression in LNCaP cells 
(Zhu et al. 2010). Altogether, identification of these 
compounds among our hits indicate that drugs with 
known antiproliferative effects in prostate cancer cells, 
including AR targeting agents, are also able to reduce 
the viability of both LNCaP-par and LNCaP-abl cells 
in our screen. This suggests that targeting AR is a po-
tent way to also reduce LNCaP-abl cell viability. 
 
Different molecular pathways are targeted by 
LNCaP-abl-selective compounds 
We chose the seven most potent LNCaP-abl selective 
anti-proliferative compounds for further validation 
based on the HTS results. The cell viability results for 
these compounds, AA-816, harmine, tanshinone IIA, 
pinosylvin methyl ether, 2,3-dimethoxy-1,4-
naphthoquinone (Alexan), cytosine-1-beta-D-
arabinofuranoside hydrochlorid (Cytarabine) and 
ZM449829 in LNCaP-abl, LNCaP-par and non-
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Figure 2. The normalized cell viability (loess score) values presented for seven cancer cell selective anti-proliferative hit com-
pounds identified in both high-throughput screens performed in androgen ablated (LNCaP-abl) cells. For comparison, the cor-
responding cell viability results are presented also for LNCaP cells grown in the presence of androgens (LNCaP-par) as well as 
for two non-malignant prostate epithelial cells (EP156T and RWPE-1).  
malignant prostate epithelial cells (RWPE1 and 
EP156T) are presented in Figure 2. Interestingly, 
analysis of known mechanisms of action for these 
compounds indicated that they target different molecu-
lar pathways. For example, AA-816 is a 5-
lipoxygenase inhibitor that blocks arachidonic acid 
induced prostate cancer cell proliferation (Steele et al. 
1999) whereas harmine, a natural compound in me-
dicinal plants (Peganum harmala and Eurycoma longi-
folia), regulates VEGF, tissue inhibitor metalloprote-
ase (TIMP), matrix metalloproteases MMP-2 and 
MMP-9 and interleukin 2 (IL-2) expression in breast 
cancer cells, induces apoptosis in hepatocellular carci-
noma cells as well as sensitizes breast cancer cells to 
mitoxantrone and camptothecin (Cao et al. 2011, Chen 
et al. 2005, Dai et al. 2012, Hamsa & Kuttan 2010, Li 
et al. 2011). Harmine has also been patented as an an-
drogen receptor inhibitor (US Patent 8119660). Other 
LNCaP-abl-selective hit compounds identified in our 
screen included the DNA damaging agent Alexan that 
has been used as a tool to study the effect of reactive 
oxygen species (Morgan 1995), a chemotherapy agent 
cytarabine that has been studied in phase II trials for 
treatment of castration-resistant prostate cancer (Dhani 
et al. 2012) as well as ZM 449829, a Janus kinase 
(JAK) and epidermal growth factor receptor (EGFR) 
inhibitor (Luo & Laaja 2004). 
 
PSME, tanshinone IIA and cytarabine are the most 
effective anti-proliferative hits in LNCaP-abl cells 
To investigate the antiproliferative effect of the seven 
selected compounds in more detail, we first deter-
mined the EC50 values for each of the compounds in 
both LNCaP-abl and LNCaP-par cells. The results 
confirmed that all seven compounds inhibited LNCaP-
abl cell viability (Table 1). However, only PSME, tan-
shinone IIA and cytarabine inhibited LNCaP-abl cell 
growth at low nanomolar concentrations. Since cytara-
bine is already in clinical trials for androgen independ-
ent prostate cancer, we selected PSME and Tanshinone 
IIA for further analyses.  
 
PSME and tanshinone IIA induce apoptosis in 
LNCaP-abl cells 
Next, we determined whether the observed decrease in 
cell viability in response to PSME and tanshinone IIA 
exposure in LNCaP-abl cells is due to induction of 
apoptosis. Caspase 3 and 7 activities were determined 
in response to 24-hour PSME or tanshinone IIA expo-
sure using an ApoONE assay (Promega). The results 
indicated that PSME and tanshinone IIA induce cas-
pase 3 and 7 activities at 10 µM concentrations in 
LNCaP-abl cells (Figure 3A and B).  
 
PSME and Tanshinone IIA effects on AR and PSA 
To find out whether PSME or tanshinone IIA affect 
AR and prostate specific antigen (PSA) expression, 
LNCaP-abl and LNCaP-par cells were exposed to 
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Compound 
LNCaP-par 
EC50 (nM) 
LNCaP-abl 
EC50 (nM) 
AA-816 >10 000 5300 
Harmine >10 000 4950 
Tanshinone IIA 360 440 
2,3-Dimethoxy-1,4-
naphthoquinone (Alexan) 
4500 2460 
Cytosine-1-beta-D-
arabinofuranoside Hydrochlorid 
(Cytarabine) 
5200 320 
ZM 449829 >10 000 2100 
Pinosylvin methyl ether 
(PSME) 
>1000 250 
Table 1. EC50 values of seven compounds in LNCaP-abl 
and LNCaP-par cells. The high-throughput screen identified 
these compounds among cancer cell selective anti-
proliferative hits in LNCaP-abl cells. 
Figure 3. Apoptosis assay to measure induction of caspase 3 and 7 activity in PSME- and tanshinone IIA-exposed LNCaP-abl 
cells.  
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Figure 4. Analysis of PSME- and tanshinone IIA-induced effects on androgen receptor (AR) and prostate specific antigen 
(PSA) expression in LNCaP cells grown in androgen ablation (AA) or in presence of androgens (par). (A) Analysis of AR and 
PSA mRNA expression by quantitative PCR. (B) Analysis of AR and PSA protein expression using Western blot analysis. β-
actin was used as an endogenous control. 
1 µM concentration of compounds for 24 or 48 hours. 
Results from quantitative RT-PCR indicated that in-
stead of a decrease, a small increase in AR mRNA ex-
pression was seen in response to PSME and tanshinone 
IIA at the 24-hour time point in both LNCaP-abl and 
LNCaP-par cells (30% and 18% increase in LNCaP-
abl cells, p < 0.05 and 22% and 38% increase in 
LNCaP-par cells, p < 0.05, respectively). At the 48-
hour time point, PSME induced a statistically signifi-
cant increase in AR mRNA expression in LNCaP-par 
cells (30% increase, p<0.01) whereas in LNCaP-abl 
cells, AR mRNA expression was not altered compared 
to vehicle control. A similar change was observed in 
AR mRNA expression in response to 48-hour tanshi-
none IIA exposure in LNCaP-par cells (55% increase, 
p<0.01). Surprisingly, however, a significant decrease 
in PSA mRNA expression in response to PSME and 
tanshinone IIA was seen in both LNCaP-abl and 
LNCaP-par cells at both 24-hour and 48-hour time 
points; PSME reduced PSA mRNA expression by 35% 
and 40% and tanshinone IIA by 60 % and 80 % at both 
time points in LNCaP-abl and LNCaP-par cells, re-
spectively (Figure 4A).  
 To find out whether PSME and tanshinone IIA 
induce similar alterations in AR and PSA expression at 
protein level, protein lysates were prepared and ran on 
SDS-PAGE gels followed by Western blot analysis. 
The results indicated that PSME reduced both AR and 
PSA protein expression in both LNCaP-abl and 
LNCaP-par cells at the 48-hour time point (Figure 4B) 
whereas tanshinone IIA-reduced AR protein expres-
sion was only seen after a 48-hour exposure in LNCaP
-abl cells. Interestingly, the PSME-induced decrease in 
AR expression was stronger in LNCaP–abl cells as 
compared to the LNCaP-par cells, indicating that dif-
ferences in AR protein expression may at least partly 
explain the PSME-induced increase in sensitivity seen 
in LNCaP-abl cells, compared to the sensitivity in 
LNCaP-par cells. Results from tanshinone IIA-
exposed LNCaP cells further support this hypothesis as 
a decrease in AR protein expression was only seen in 
tanshinone IIA-sensitive LNCaP-abl cells at the 48 
hour timepoint. 
 
PSME and tanshinone IIA alter the expression of 
genes involved in multiple cellular processes 
To gain further insights into PSME and tanshinone IIA 
induced alterations in prostate cancer cells and to bet-
ter understand the differential sensitivity of LNCaP-abl 
and LNCaP- par cells to the compounds, genome‑wide 
gene expression analysis of PMSE and tanshinone IIA-
exposed LNCaP‑abl and LNCaP-par cells was per-
formed. The gene expression in PSME and tanshinone 
IIA vs. DMSO- (vehicle control) exposed cells (24 
hours) were compared and the most significantly al-
tered biological processes were determined using the 
Ingenuity Pathway Analysis software. The analysis of 
PSME and tanshinone IIA modulated pathways indi-
cated that the most differentially expressed genes in 
response to PSME or tanshinone IIA were involved in 
steroid and cholesterol metabolism (p-values of 1,10E-
06 to 1,64E-03) as well as cell cycle regulation and 
stress response pathways (p-values of 1.81E-09 to 
2.79E-04) (Supplementary Table 3). Moreover, cellu-
lar processes such as cellular movement and develop-
ment were altered both in response to PSME and tan-
shinone IIA, indicating that these compounds may 
contribute to multiple biological processes in addition 
to cell viability and apoptosis. 
 Our results from AR mRNA expression analy-
sis indicated that AR mRNA levels did not decrease in 
response to PSME or tanshinone IIA exposure in 
LNCaP cells, indicating that the decrease in AR pro-
tein expression is likely to be controlled by other 
means than by direct regulation of AR transcription. 
Also, there was no clear relationship between AR and 
PSA protein levels in response to PSME and tanshi-
none IIA exposure, indicating that AR signalling 
measured by PSA does not directly correlate with AR 
protein expression. To get clues on putative modula-
tors of AR signalling, we focussed our analysis on 
lipid metabolism-related changes in PSME- and tan-
shinone IIA-exposed LNCaP-abl cells. Indeed, lipid 
metabolism related changes were identified in both 
tanshinone IIA- and PSME-exposed cells, as evi-
denced by altered expression of aldo-keto reductases 
AKR1C2, AKR1C3 and AKR1C4 in response to 
PSME, and Methylsterol Monooxygenase 1 (MSMO1/ 
SC4MOL), Squalene Monooxygenase (SQLE), ATP-
Binding Cassette Sub-Family G Member 1 (ABCG1) 
and proprotein convertase subtilisin kexin 9 (PCSK9) 
in response to tanshinone IIA in LNCaP-abl cells. In-
terestingly, similar results were not seen in LNCaP-par 
cells where most enriched pathways included cell cy-
cle regulation and stress pathways (Supplementary 
Table 3). Previous studies have indicated that MSMO1 
and SQLE are involved in cholesterol metabolism and 
also ABCG1 expression is regulated by cholesterol and 
plays an important role in macrophage lipid homeosta-
sis (Kennedy et al. 2005, Out et al. 2008, Souchek et 
al. 2014, Vaughan & Oram 2005). PCSK9 is a recently 
discovered protein, whose high activity results in hy-
percholesterolemia and has been suggested as a novel 
drug target for invasive cancers (Seidah 2013). PSME- 
induced changes in lipid metabolism were linked to 
reduced aldo-keto reductase expression (AKR1C2, 
AKR1C3 and AKR1C4) in LNCaP-abl cells (Figure 
5A). Aldo-keto reductases are enzymes involved in 
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steroidogenesis and catalyze the conversion of alde-
hydes and ketones to their corresponding alcohols by 
utilizing NADH and/or NADPH as cofactors (Figure 
5B). Aldo-keto reductases also regulate testosterone 
levels in prostate cancer (Penning & Byrns 2009) and 
aldo-keto reductase AKR1C3 is a known cofactor of 
the androgen receptor (AR) and inducer of AR signal-
ing in prostate cancer (Yepuru et al. 2013). Taken to-
gether, analysis of tanshinone IIA- and PSME-induced 
changes in LNCaP-abl cells using genome-wide gene 
expression profiling revealed alterations in multiple 
biological processes and provided insights into tanshi-
none IIA- and PSME-induced changes in steroido-
genesis.  
 
Discussion 
 
Prostate cancer remains the most common cancer in 
the western male population. Although several novel 
drugs improving prostate cancer patient survival have 
been identified, there is no cure for prostate cancer 
patients suffering from a castration-resistant disease. 
Here, we utilized a cell-based high-throughput chemi-
cal biology screen to identify anti-proliferative com-
pounds for castration-resistant prostate cancer (CRPC) 
and to explore the key targetable molecular pathways 
in CRPC. As a model, we used parental (par) and an-
drogen ablated (abl) LNCaP cells and compared drug 
effects into those in non-malignant RWPE-1 and 
EP156T prostate cells screened previously (Iljin et al. 
2009). A total of 44 cancer-selective anti-proliferative 
hits were identified in LNCaP-abl cells and out of 
these, 12 compounds were found to be already, either 
in clinical use, in clinical trials or preclinical studies in 
prostate cancer, validating the functionality of our 
screen. Seven most potent anti-proliferative com-
pounds were selected for further validation and two of 
these, pinosylvin methyl ether (PSME) and tanshinone 
IIA, were identified as potent inhibitors of LNCaP-abl 
cell viability. 
 Tanshinone IIA is a compound originally ex-
tracted from Danshen (Radix Salviae Miltiorrhizae). It 
has been used in traditional Chinese medicine for car-
diovascular diseases. In addition to our results in pros-
tate cancer cells, Tanshinone IIA has been shown to 
have anti-neoplastic potential in leukemic, breast, co-
lon and hepatocellular carcinoma cells (Cheng & Su 
2010, Chiu & Su 2010, Jiao & Wen 2011, Su & Lin 
2008, Wang et al. 2005). Recently, tanshinone IIA was 
also shown to reduce prostate cancer cell growth in PC
-3 and LNCaP cells both in vitro and in vivo (Won et 
al. 2010, Won et al. 2012, Zhang et al. 2012). Our re-
sults indicate that tanshinone IIA inhibits also andro-
gen ablated LNCaP cell proliferation at nanomolar 
concentrations, suggesting that this compound may 
also have therapeutic potential in CRPC. 
 Pinosylvin methyl ether (PSME) is a stilbene 
compound that is isolated from green alder (Bryant et 
al. 1983). It has a similar structure to resveratrol, a 
widely studied antineoplastic compound studied in 
different cancers (ElAttar & Virji 1999, Hsieh & Wu 
1999, Jang et al. 1997, Jang & Pezzuto 1999, Lu & 
Serrero 1999). However, although resveratrol was 
among the screened compounds, it did not come up as 
an anti-proliferative hit in our screen. To our knowl-
edge PSME has not been previously studied nor pro-
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Figure 5. Analysis of aldo-keto reductase (AKCR) mRNA 
expression and steroidogenesis pathway alterations in  
PSME-exposed LNCaP abl cells. (A) Gene expression al-
terations in aldo-ketoreductase AKR1C2-4 mRNA levels in 
LNCaP-abl cells. Relative AKR1C2, AKR1C3 and 
AKR1C4 mRNA expression is presented as fold change to 
vehicle exposed cells. (B) AKRC enzymes in steroid hor-
mone metabolism pathway. Green: downregulation of 
AKR1C3 and AKR1C4 gene expression. 
posed as an anti-proliferative compound in any cancer.  
 Importantly, both tanshinone IIA and PSME 
decreased AR protein expression as well as PSA 
mRNA and protein expression in LNCaP-abl cells. 
Genome-wide gene expression analyses indicated that 
in addition to cell cycle regulation, both tanshinone 
IIA and PSME may modulate multiple biological proc-
esses such as the steroid / cholesterol metabolism. In-
terestingly, the expression of aldo-keto reductases 
AKR1C2, AKR1C3 and AKR1C4 was decreased in 
castration-resistant LNCaP cells in response to PSME 
exposure. Aldo-keto reductases induce steroidogenesis 
and AKR1C3 is a biomarker and therapeutic target for 
CRPC (Adeniji et al. 2013, Hamid et al. 2012). Re-
cently, other pinosylvin derivatives have been pro-
posed to be potential AKR1C3 inhibitors, in a virtual 
screening of a fragment library (Brozic et al. 2012). 
This further supports our hypothesis of PSME as a 
novel AKR1C3 inhibitor. Thus, PSME is of interest 
while developing novel treatment options for CRPC 
targeting AKR1C3-induced AR signalling.  
 Taken together, this systematic screen identi-
fied a novel anti-proliferative agent, PSME, for CRPC. 
PSME reduces androgen signaling and intracellular 
steroidogenesis evidenced by downregulation of AR 
and PSA protein levels and aldo-keto reductase expres-
sion in CRPC cells in vitro. Moreover, our screen con-
firmed tanshinone IIA as well as several other com-
pounds as potential prostate cancer growth inhibitors 
in androgen ablated prostate cancer cells. These results 
provide interesting starting points for the design of 
preclinical and clinical approaches for CRPC treat-
ment. 
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